Illustrative packaging · Research use only
Metabolic & incretin
GLP/GIP (TIRZ)
Choose a specification
1 pack · 10 vials total
Guest checkout is available. Create an account before your first request to receive the eligible 15% welcome offer.
Choose your payment method at checkout to see the total and next payment steps. No administration or personal-use guidance is provided.
Receptor-signaling and pancreatic-islet experiments
What the research examines
Tirzepatide was characterized as a dual GIP/GLP-1 receptor agonist with unequal receptor engagement. The study compared cAMP generation, beta-arrestin recruitment and receptor internalization, with additional experiments in primary pancreatic islets.
Potential research applications
Potential experimental applications include comparing signaling bias and receptor trafficking across incretin pathways.
These are research questions drawn from the cited work, not established applications of this supplied material.
Evidence limits
Receptor and islet findings describe the tested systems. They do not establish the potency, purity or clinical performance of a separately supplied material.
Material identity and presentation
Powder vial artwork is conceptual; actual form and packaging unverified. Published findings do not establish the identity, purity or performance of an individual supplied material.
